tricuspid

Tricuspid Valve Transcatheter Edge-to-Edge Repair in the “Real World”

Tricuspid valve transcatheter edge-to-edge repair (T-TEER) is currently under development, with an increasing number of conducted procedures. While the TRILUMINATE Study did not reveal benefit regarding major events, it did show improvements in quality of life. In the real world, we encounter numerous patients who do not meet the study criteria but still experience symptoms<a href="https://solaci.org/en/2024/03/08/tricuspid-valve-transcatheter-edge-to-edge-repair-in-the-real-world/" title="Read more" >...</a>

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Health Status Scores after Transcatheter Repair in Patients with Tricuspid Regurgitation: TRILUMINATE Analysis

Severe tricuspid regurgitation (TR) has been associated with higher mortality and significant limitations to patient quality of life, with considerable rates of hospitalization for cardiac failure (CF). Transcatheter edge-to-edge repair (TEER) with TriClip has been shown effective to reduce symptoms, with low risk of periprocedural complications.&nbsp; The aim of this study was to assess functional<a href="https://solaci.org/en/2024/01/17/health-status-scores-after-transcatheter-repair-in-patients-with-tricuspid-regurgitation-triluminate-analysis/" title="Read more" >...</a>

intervencion percutanea

Tricuspid Regurgitation: Natural Progression and Prognosis

The prevalence of tricuspid regurgitation (TR) is significant; its prognosis is well known, and severe TR stages are associated with higher mortality and hospitalization for cardiac failure (CF). Seeing as valve disease tends to evolve over time, in advanced stages, we usually check on patients at specified intervals for early identification of potential hemodynamic complications<a href="https://solaci.org/en/2023/12/19/tricuspid-regurgitation-natural-progression-and-prognosis/" title="Read more" >...</a>

Sistema EVOQUE: reemplazo tricuspídeo transcatéter, resultados al año

EVOQUE: Transcatheter Tricuspid Valve Replacement, One-Year Outcomes

Treating tricuspid regurgitation (TR) has gained increasing importance in interventionism. There is abundant literature on the negative natural evolution of this condition and its unfavorable prognosis, as well as the clinical challenges associated to optimal medical treatment.&nbsp; Among its percutaneous treatment options, both edge-to-edge repair devices (TEER), as showed in TriValve and TRILUMINATE trials, and<a href="https://solaci.org/en/2023/12/15/evoque-transcatheter-tricuspid-valve-replacement-one-year-outcomes/" title="Read more" >...</a>

Intervención tricuspídea heterotópica: Resultados de TricValve a un año

Heterotopic Tricuspid Intervention: TricValve One-Year Outcomes

Severe tricuspid regurgitation (TR) presents a reserved prognosis when not treated in time, seeing as systemic venous congestion might significantly limit quality of life in these patients. For many years it was thought diuretic therapy was the only option to treat these patients, since the surgical alternative offered suboptimal results and many patients were deemed<a href="https://solaci.org/en/2023/12/11/heterotopic-tricuspid-intervention-tricvalve-one-year-outcomes/" title="Read more" >...</a>

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

Latest Developments in Tricuspid Regurgitation

The natural history of tricuspid regurgitation is associated to hospitalization for cardiac failure and mortality. This is why the AHA/ACC guidelines recommend surgery when the tricuspid fails during left valve surgical repair, because its slow progression is associated with high mortality (35%). Many of these patients are high risk and percutaneous intervention has surged as<a href="https://solaci.org/en/2023/05/12/latest-developments-in-tricuspid-regurgitation/" title="Read more" >...</a>

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Sex-Related Differences in Clinical Outcomes after Transcatheter Tricuspid Valve Intervention

We are aware of sex related differences when it comes to comorbidities, physiopathology and disease evolution in patients with tricuspid regurgitation (TR).&nbsp; TR is more prevalent among women, whereas among men, coronary artery disease is more prevalent, with worse left ventricular ejection fraction and 10-year survival rate. Transcatheter tricuspid valve intervention (TTVIs) has surged as<a href="https://solaci.org/en/2023/04/26/sex-related-differences-in-clinical-outcomes-after-transcatheter-tricuspid-valve-intervention/" title="Read more" >...</a>

Sobrevida en pacientes con insuficiencia tricuspídea según variables clínicas y ecocardiográficas (Clusters)

Survival in Patients with Tricuspid Regurgitation According to Clinical and Echocardiographic Variables (Clusters)

Survival analysis of patients with tricuspid regurgitation grouped according to comorbidities and echocardiographic variables. For many years, the tricuspid was classified as the “forgotten valve,” due to the scarce possibility of treatment beyond symptom control in patients with heart failure. However, in recent years, there has been an improvement in the treatment of the valve<a href="https://solaci.org/en/2023/03/28/survival-in-patients-with-tricuspid-regurgitation-according-to-clinical-and-echocardiographic-variables-clusters/" title="Read more" >...</a>

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

TriClip: Tricuspid Regurgitation Dedicated Device

Severe tricuspid regurgitation (TR) is difficult to manage and is associated to high morbimortality.&nbsp; Surgical repair is complex and not free from complications: its mortality rate ranges from 5 to 20% and depends on series, surgeon and center expertise. Edge-to-edge repair with clips has become a valid alternative to treat this disease, but most data<a href="https://solaci.org/en/2023/03/22/triclip-tricuspid-regurgitation-dedicated-device/" title="Read more" >...</a>

Top